Search results
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
FOX 23 News Albany· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 2 days agoSupported by robust data from two Phase 3 clinical trials, INSPIRE and...Skyrizi’s potential to become a cornerstone therapy in AbbVie’s portfolio, particularly as a successor to its blockbuster ...
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks· 23 hours agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
Gateway - Quartz
Quartz· 4 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar drug that dominates a market, brings in hordes of customers, and deposits ...
First Financial Bank Trust Division Has $345,000 Position in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 3 days agoFirst Financial Bank Trust Division lowered its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.2% during the first quarter, according to the company in its most recent Form 13F filing ...
AbbVie Inc. (NYSE:ABBV) Shares Bought by First Financial Bank Trust Division
ETF DAILY NEWS· 3 days agoFirst Financial Bank Trust Division boosted its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 967.2% during the 1st quarter, according to the company in its most recent disclosure ...
General Partner Inc. Buys 1,792 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 3 days agoGeneral Partner Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 716.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission ...